The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial

The vasopressin V2 receptor antagonist tolvaptan delays the progression of autosomal dominant polycystic kidney disease (ADPKD). However, some patients discontinue tolvaptan because of severe adverse aquaretic events. This open-label, randomized, controlled, counterbalanced, crossover trial investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Uchiyama, Kiyotaka, Kitayama, Chigusa, Yanai, Akane, Ishibashi, Yoshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417075/
https://www.ncbi.nlm.nih.gov/pubmed/34480075
http://dx.doi.org/10.1038/s41598-021-97113-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417075/
https://www.ncbi.nlm.nih.gov/pubmed/34480075
http://dx.doi.org/10.1038/s41598-021-97113-w

Ejemplares similares